Literature DB >> 21725799

Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer.

Anand G Patil1, Russell D'Souza, Neeta Dixit, Anagha Damre.   

Abstract

Although quinidine has been recommended as a probe substrate for the P-gp inhibition assay using Caco-2 cell monolayer, it has not been studied widely in the in vitro system. In the present investigation, in vitro permeability studies using Caco-2 cell monolayer were carried out in order to optimize and validate quinidine as a P-gp probe substrate. In bi-directional Caco-2 assay across different passages, a good efflux ratio of more than ten was consistently obtained at 100 nM donor concentration of quinidine. Quinidine was found to have a good mass balance in the Caco-2 system. The inhibitory potencies of known P-gp inhibitors viz verapamil, ketoconazole, tacrolimus and cyclosporine A, determined over a wide concentration range, showed low apparent IC(50) values. Overall, quinidine was found to be a good probe substrate for routine use to assess the in vitro inhibitory potency of NCEs on Pgp-mediated transport.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21725799     DOI: 10.1007/s13318-011-0046-9

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  14 in total

Review 1.  Does inhibition of P-glycoprotein lead to drug-drug interactions?

Authors:  David Balayssac; Nicolas Authier; Anne Cayre; François Coudore
Journal:  Toxicol Lett       Date:  2005-01-18       Impact factor: 4.372

2.  Pharmacokinetic analysis of transcellular transport of quinidine across monolayers of human intestinal epithelial Caco-2 cells.

Authors:  Kazuya Ishida; Mari Takaai; Yukiya Hashimoto
Journal:  Biol Pharm Bull       Date:  2006-03       Impact factor: 2.233

Review 3.  Current industrial practices of assessing permeability and P-glycoprotein interaction.

Authors:  Praveen V Balimane; Yong-Hae Han; Saeho Chong
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

4.  Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates.

Authors:  Timo Korjamo; Heidi Kemiläinen; Aki T Heikkinen; Jukka Mönkkönen
Journal:  Drug Metab Dispos       Date:  2007-06-04       Impact factor: 3.922

5.  Development and validation of RP-HPLC-fluorescence method for quantitative determination of quinidine, a probe substrate for P-glycoprotein inhibition assay using Caco-2 cell monolayer.

Authors:  Anand G Patil; Dilip Reddy; Russell D'Souza; Anagha Damre
Journal:  Biomed Chromatogr       Date:  2010-06       Impact factor: 1.902

Review 6.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

7.  Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.

Authors:  S Ibrahim; J Peggins; A Knapton; T Licht; A Aszalos
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

8.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.

Authors:  Qing Wang; Joseph D Rager; Kathryn Weinstein; Paula S Kardos; Glenn L Dobson; Jibin Li; Ismael J Hidalgo
Journal:  Int J Pharm       Date:  2004-12-15       Impact factor: 5.875

9.  Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.

Authors:  Yoshiyuki Shirasaka; Masae Kawasaki; Toshiyasu Sakane; Hideaki Omatsu; Yuka Moriya; Tsutomu Nakamura; Toshiyuki Sakaeda; Katsuhiko Okumura; Peter Langguth; Shinji Yamashita
Journal:  Drug Metab Pharmacokinet       Date:  2006-10       Impact factor: 3.614

10.  Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring.

Authors:  Gunilla Englund; Pär Hallberg; Per Artursson; Karl Michaëlsson; Håkan Melhus
Journal:  BMC Med       Date:  2004-04-02       Impact factor: 8.775

View more
  4 in total

1.  Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.

Authors:  Ha T Do; Huiying Li; Georges Chreifi; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2019-02-25       Impact factor: 7.446

2.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

3.  Improvement of Cell Permeability of Human Neuronal Nitric Oxide Synthase Inhibitors Using Potent and Selective 2-Aminopyridine-Based Scaffolds with a Fluorobenzene Linker.

Authors:  Ha T Do; Heng-Yen Wang; Huiying Li; Georges Chreifi; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2017-11-01       Impact factor: 7.446

4.  Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.

Authors:  Jasleen K Sodhi; Shuaibing Liu; Leslie Z Benet
Journal:  Pharm Res       Date:  2020-09-29       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.